News | EP Mapping and Imaging Systems | October 09, 2019

Acutus Medical and Innovative Health Collaborate to Increase Patient Access to Electrophysiology Care

Companies will enter a partnership that offers hospitals Acutus technology together with regulated reprocessing of single-use devices

Acutus Medical and Innovative Health Collaborate to Increase Patient Access to Electrophysiology Care

October 9, 2019 — Acutus Medical and Innovative Health announced a partnership that will offer advanced electrophysiology technology to improve patient outcomes in a cost-efficient manner. The two high profile venture-backed companies will team to offer hospital customers a comprehensive suite of EP products, including Acutus’ next-generation EP mapping and accessory products together with a growing portfolio of reprocessed single-use EP devices from a range of manufacturers.

Acutus will also work proactively with Innovative Health to gain clearances, as appropriate, to market reprocessed versions of certain proprietary Acutus products – a highly novel approach for a venture-backed device company. The goal of the partnership is to simultaneously rein in per-procedure costs while freeing up hospital budget dollars for emerging new technologies that hold the prospect of improving clinical outcomes and speeding up procedure times.

Recognizing the constraints that hospitals and health systems face in delivering quality patient care at a sustainable cost is fundamental in the current healthcare environment.  Safe, proven and effective reprocessing of high-cost single-use devices offers a reliable avenue for hospitals to combine the best of both worlds: best-in-class, state-of-the-art technologies together with cost-effective, sustainable per-procedure costs.

Acutus provides a full suite of technologies and products for electrophysiology diagnostic and ablation procedures through an open platform that enables personalized and adaptive approaches to arrhythmia therapy.  

Innovative Health is a specialty EP reprocessing company that collects, reprocesses and returns single-use labeled EP catheters to hospitals, reducing each atrial fibrillation (AF) procedure’s device costs by as much as 30 percent. The company holds formal U.S. Food and Drug Administration (FDA) clearances to reprocess many high-complexity EP devices, such as mapping catheters, diagnostic ultrasound catheters and introducer sheaths. This allows Innovative Health hospital partners to increase their savings compared to other reprocessing programs. 

For more information: www.acutusmedical.com, www.innovative-health.com

Related Content

Lenox Hill Hospital Opens New Heart Rhythm Center
News | EP Lab | August 27, 2019
Lenox Hill Hospital (New York, N.Y.) has established a brand new Heart Rhythm Center dedicated to the treatment of...
Damaged Hearts Rewired With Nanotube Fibers

Researchers at Texas Heart Institute and Rice University have confirmed that flexible, conductive fibers made of carbon nanotubes can bridge damaged tissue to deliver electrical signals and keep hearts beating despite congestive heart failure or dilated cardiomyopathy or after a heart attack. Image courtesy of Texas Heart Institute.

News | EP Lab | August 15, 2019
Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the...
Cardiac Device Complications Vary Widely Among Hospitals
News | EP Lab | July 31, 2019
The chances of patients experiencing complications after having a cardiac device implanted vary according to where they...
A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively 

News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] Th
Studies Find Race and Gender Disparities in Implantable Heart Devices
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, includ
Heart Rhythm 2019 study shows travelers with common cardiac devices can pass through without restrictions or precautions. HRS 2019, #HRS #HRS19

A new study shows travelers with common cardiac devices can pass through airport body scanners without restrictions or precautions.

News | EP Lab | May 14, 2019
May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), su
News | EP Lab | May 13, 2019
May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their
Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Feature | EP Lab | March 22, 2019
March 22, 2019 — The U.S.
Overlay Init